Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hMaxi-K gene therapy - Urovant Sciences

Drug Profile

hMaxi-K gene therapy - Urovant Sciences

Alternative Names: hMaxi-K - Ion Channel Innovations; hMaxi-K; URO-902

Latest Information Update: 20 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ion Channel Innovations LLC
  • Developer Ion Channel Innovations
  • Class Erectile dysfunction therapies; Gene therapies; Urologics
  • Mechanism of Action Calcium-activated potassium channel openers; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Overactive bladder
  • No development reported Erectile dysfunction

Most Recent Events

  • 26 Jun 2019 Ion Channel Innovations terminates a phase I trial in Overactive bladder in USA due to slow enrolment and financial issues (Intravesicular) (NCT00495053)
  • 31 Aug 2018 Discontinued - Phase-I for Erectile dysfunction in USA (Intracavernous)
  • 28 Aug 2018 hMaxi-K gene therapy licensed to Urovant Sciences worldwide for the treatment of Overactive bladder (Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top